Recursion Pharmaceuticals, Inc. RXRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$117.5M-8.7% | -$108.12M+33.4% | -$162.25M+5.6% | -$171.9M+15.1% | -$202.49M-13.2% | ||
| $19.67M+1.0% | $19.48M-7.4% | $21.04M-11.8% | $23.85M+23.4% | $19.33M+49.3% | ||
| $22.22M-6.5% | $23.76M-5.9% | $25.24M-3.5% | $26.16M-27.5% | $36.06M+17.1% | ||
| -$4.6M— | —— | —— | —— | -$419K— | ||
| $0— | —— | —— | —— | -$4.5M— | ||
| $2.07M— | —— | -$5.89M-21.8% | -$4.84M-231% | $3.69M-54.5% | ||
| -$18.45M— | —— | -$8.03M— | —— | -$26.59M-353% | ||
| -$14.75M— | $0+100% | -$3.53M+86.1% | -$25.41M-425% | -$4.84M-355% | ||
| -$1.67M+42.2% | -$2.9M— | —— | -$4.27M+11.4% | -$4.82M+71.6% | ||
| -$2.25M+66.7% | -$6.76M-1.9% | -$6.63M+51.3% | -$13.62M-39.5% | -$9.76M-72.4% | ||
| -$81.1M-76.0% | -$46.07M+60.7% | -$117.36M-53.6% | -$76.42M+42.1% | -$131.96M-14.3% | ||
| $258K-79.3% | $1.24M+412% | $243K-92.3% | $3.15M+71.9% | $1.83M+41.1% | ||
| $0— | $0-100% | $2.31M+361% | $500K-50.0% | $1M— | ||
| $0— | —— | —— | —— | -$4.44M— | ||
| $80K— | —— | —— | $2.16M— | $0-100% | ||
| -$338K+72.8% | -$1.24M+51.2% | -$2.55M+56.1% | -$5.81M+20.1% | -$7.27M-103% | ||
| $2.21M+1.9% | $2.17M+1.9% | $2.13M+2.1% | $2.08M+1.8% | $2.05M-2.6% | ||
| $0-100% | $133.38M-47.6% | $254.46M+154% | $100M+144% | $41.02M+272% | ||
| -$3.47M-103% | $132.01M-47.5% | $251.34M+157% | $97.66M+141% | $40.53M+281% | ||
| -$3.83M-284% | $2.09M+11.7% | $1.87M-79.8% | $9.26M+91.5% | $4.83M+239% | ||
| -$88.74M-202% | $86.78M-34.9% | $133.3M+440% | $24.69M+126% | -$93.87M-156% | ||
| $0— | —— | —— | —— | -$4.5M— | ||
| $730K— | —— | -$4.06M-438% | -$754K-226% | $599K— | ||
| -$4.65M-20.4% | -$3.86M+25.9% | -$5.22M-1.3% | -$5.15M+10.6% | -$5.76M-29.1% | ||
| -$18.45M— | —— | -$8.03M— | —— | -$26.59M-353% | ||
| -$14.75M— | $0+100% | -$3.53M+86.1% | -$25.41M-425% | -$4.84M-355% | ||
| $0+100% | -$20.26M— | $0+100% | -$2.47M+90.9% | -$27.13M-332% | ||
| -$1.67M+42.2% | -$2.9M— | —— | -$4.27M+11.4% | -$4.82M+71.6% | ||
| $0— | —— | —— | —— | $5.96M— | ||
| $80K— | —— | —— | $2.16M— | $0-100% | ||
| $0— | —— | —— | —— | -$4.44M— | ||
| -$1.26M— | —— | —— | —— | $1.55M— | ||
| $2.21M+1.9% | $2.17M+1.9% | $2.13M+2.1% | $2.08M+1.8% | $2.05M-2.6% | ||
| $0+100% | -$29K— | —— | —— | $1.15M+465% | ||
| -$2.25M+66.7% | -$6.76M-1.9% | -$6.63M+51.3% | -$13.62M-39.5% | -$9.76M-72.4% | ||
| $1.92M— | $0— | $0— | $0— | $0-100% | ||
| $5.24M+0.2% | $5.23M-0.6% | $5.26M-6.4% | $5.63M-8.2% | $6.13M+12.3% | ||
| $0— | —— | —— | —— | $4.44M— | ||
| -$81.36M-71.9% | -$47.32M+59.8% | -$117.6M-47.8% | -$79.57M+40.5% | -$133.79M-14.6% | ||
| -$81.36M-71.9% | -$47.32M+59.8% | -$117.6M-47.8% | -$79.57M+40.5% | -$133.79M-14.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Recursion Pharmaceuticals, Inc. generate?
- Recursion Pharmaceuticals, Inc. (RXRX) generated -$321.0M in operating cash flow over the trailing twelve months.
- What is Recursion Pharmaceuticals, Inc.'s free cash flow?
- After $4.9M of capital expenditures, Recursion Pharmaceuticals, Inc.'s free cash flow was -$325.8M over the trailing twelve months, up 18.1% year over year.
- Where does Recursion Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
